.Pharmacolibrary.Drugs.V_Various.V10X_OtherTherapeuticRadiopharmaceuticals.V10XX04_Lutetium177luOxodotreoti.Lutetium177luOxodotreoti .Pharmacolibrary.Drugs.V_Various.V10X_OtherTherapeuticRadiopharmaceuticals.V10XX04_Lutetium177luOxodotreoti.Lutetium177luOxodotreoti| name: | Lutetium177luOxodotreotide | |
| ATC code: | V10XX04 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 7400 | mg |
| volume of distribution: | 18 | L |
| clearance: | 0.19 | L/h |
| other parameters in model implementation | ||
Lutetium (177Lu) oxodotreotide is a radiolabeled somatostatin analog used in peptide receptor radionuclide therapy (PRRT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It binds to somatostatin receptors overexpressed on tumor cells, allowing targeted delivery of beta-radiation. Approved for clinical use, notably as Lutathera.
Population pharmacokinetics in adult patients with advanced, progressive, somatostatin receptor-positive GEP-NETs after intravenous administration.